Read Our Latest Issue Genetic engineering could allow for speedy production as well Pfizer and BioNTech that their experimental vaccine against the novel coronavirus is more than 90 percent effective in preventing the disease COVID-19, based on initial analysis of results from their large phase III trial. The two companies also report that no serious safety concerns have arisen thus far. To create the vaccine, researchers genetically engineered SARS-CoV-2 genes, captured their blueprint, embedded that blueprint into an RNA molecule in solution and injected the solution into the bodies of trial participants. The full method for this approach is outlined in the graphic below ( ), which in the June 2020 issue of . The trial's data have not yet been submitted for peer-review publication. If the results hold up, Pfizer and BioNTech say they could manufacture large quantities of the genetically engineered vaccine quickly. Mark Fischetti is a senior editor at . He covers all aspects of sustainability. Credit: Nick Higgins Jen Christiansen is senior graphics editor at . 5 hours ago  --  Robert Z. Pearlman and SPACE.com 6 hours ago  --  Nidhi Subbaraman and Nature magazine 7 hours ago  --  Jean Chemnick and E&E News 14 hours ago  --  Avi Loeb | 14 hours ago  --  Marla Broadfoot January 25, 2021  --  Chelsea Harvey and E&E News Discover world-changing science. Explore our digital archive back to 1845, including articles by more than 150 Nobel Prize winners. Follow us Scientific american arabic (c) 2021 Scientific American, a Division of Springer Nature America, Inc. All Rights Reserved. Support our award-winning coverage of advances in science & technology. Already a subscriber? Subscribers get more award-winning coverage of advances in science & technology.